FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281628008> ?p ?o ?g. }

• W4281628008 endingPage "508" @default.
• W4281628008 startingPage "504" @default.
• W4281628008 abstract "Abstract Objective Irukandji syndrome (IS) is an extremely painful condition that causes a significant catecholamine surge and sympathetic autonomic response related to the envenomation from certain types of jellyfish. Current management involves intravenous fluids, magnesium sulphate and large doses of opioids for symptom control. Clonidine, a centrally acting alpha‐2 agonist, is often used as an analgesic adjunct to reduce opioid requirements in acute pain. The present study explores the safety and efficacy of clonidine in reducing opioid requirements in IS. Methods All patients diagnosed with IS at Cairns Hospital between 1 March 2016 and 30 April 2020, and participants from the Magnesium in Irukandji Study Trial, were included in this retrospective study ( n = 114). Cases were separated into two groups depending on whether or not they received clonidine, and subsequently analysed according to pre‐ and post‐intervention opioid requirements, clonidine dose administered and adverse effects. Results Notably, 39 patients with IS received ≥1 mcg/kg clonidine and the remaining 75 did not. There was no difference in oral morphine equivalent daily dose (oMEDD) between groups before clonidine administration; however, there was a significant reduction in oMEDD required after patients received clonidine (26.1 mg; 95% CI 4.6–47.7) compared with those who did not (66.6 mg; 95% CI 56.9–86.1) ( F = 8.722, df = 1 × 224, P = 0.003). One episode of hypotension occurred following the intervention. Conclusion Patients with IS who received clonidine required significantly lower opioid requirements than those who did not receive clonidine. Clonidine was safe to administer and should be considered early when treating IS. The optimal clonidine dose remains unclear and requires prospective studies to validate our findings." @default.
• W4281628008 created "2022-06-13" @default.
• W4281628008 creator A5036405095 @default.
• W4281628008 creator A5077800316 @default.
• W4281628008 creator A5081321570 @default.
• W4281628008 date "2022-05-31" @default.
• W4281628008 modified "2023-09-27" @default.
• W4281628008 title "Use of clonidine in the treatment of Irukandji syndrome: A 4‐year retrospective cohort study on safety, efficacy and clinical utility" @default.
• W4281628008 cites W1903442402 @default.
• W4281628008 cites W1969182770 @default.
• W4281628008 cites W2062587544 @default.
• W4281628008 cites W2340781653 @default.
• W4281628008 cites W2522317186 @default.
• W4281628008 cites W2588021289 @default.
• W4281628008 doi "https://doi.org/10.1111/1742-6723.14017" @default.
• W4281628008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35638940" @default.
• W4281628008 hasPublicationYear "2022" @default.
• W4281628008 type Work @default.
• W4281628008 citedByCount "2" @default.
• W4281628008 countsByYear W42816280082022 @default.
• W4281628008 crossrefType "journal-article" @default.
• W4281628008 hasAuthorship W4281628008A5036405095 @default.
• W4281628008 hasAuthorship W4281628008A5077800316 @default.
• W4281628008 hasAuthorship W4281628008A5081321570 @default.
• W4281628008 hasConcept C126322002 @default.
• W4281628008 hasConcept C141071460 @default.
• W4281628008 hasConcept C167135981 @default.
• W4281628008 hasConcept C170493617 @default.
• W4281628008 hasConcept C197934379 @default.
• W4281628008 hasConcept C2777389121 @default.
• W4281628008 hasConcept C2778399450 @default.
• W4281628008 hasConcept C2780820201 @default.
• W4281628008 hasConcept C2781063702 @default.
• W4281628008 hasConcept C42219234 @default.
• W4281628008 hasConcept C71924100 @default.
• W4281628008 hasConceptScore W4281628008C126322002 @default.
• W4281628008 hasConceptScore W4281628008C141071460 @default.
• W4281628008 hasConceptScore W4281628008C167135981 @default.
• W4281628008 hasConceptScore W4281628008C170493617 @default.
• W4281628008 hasConceptScore W4281628008C197934379 @default.
• W4281628008 hasConceptScore W4281628008C2777389121 @default.
• W4281628008 hasConceptScore W4281628008C2778399450 @default.
• W4281628008 hasConceptScore W4281628008C2780820201 @default.
• W4281628008 hasConceptScore W4281628008C2781063702 @default.
• W4281628008 hasConceptScore W4281628008C42219234 @default.
• W4281628008 hasConceptScore W4281628008C71924100 @default.
• W4281628008 hasIssue "4" @default.
• W4281628008 hasLocation W42816280081 @default.
• W4281628008 hasLocation W42816280082 @default.
• W4281628008 hasOpenAccess W4281628008 @default.
• W4281628008 hasPrimaryLocation W42816280081 @default.
• W4281628008 hasRelatedWork W1971792289 @default.
• W4281628008 hasRelatedWork W1986189789 @default.
• W4281628008 hasRelatedWork W2025235454 @default.
• W4281628008 hasRelatedWork W2032263737 @default.
• W4281628008 hasRelatedWork W2034008487 @default.
• W4281628008 hasRelatedWork W2037205979 @default.
• W4281628008 hasRelatedWork W2160450992 @default.
• W4281628008 hasRelatedWork W2374724226 @default.
• W4281628008 hasRelatedWork W2418388737 @default.
• W4281628008 hasRelatedWork W4242167546 @default.
• W4281628008 hasVolume "34" @default.
• W4281628008 isParatext "false" @default.
• W4281628008 isRetracted "false" @default.
• W4281628008 workType "article" @default.